The most well known GLP-1 medication is Ozempic, though in Australia it is only approved for the management of Type 2 ...

The Centers for Medicare and Medicaid Services (CMS) announced Friday it will not be finalizing a rule proposed by the Biden administration that would have allowed Medicare and Medicaid ...

Proponents of coverage argued treating obesity can reduce longer-term costs by cutting down on heart attacks and other health ...

The Trump administration has decided not to back a Biden administration plan that would have allowed Medicare to pay for obesity drugs, according to a report from Bloomberg. Shares of both Eli ...

Gift 5 articles to anyone you choose each month when you subscribe. The Labor-Liberal joint ticket on jacking up the nation’s award wage floor despite the economy’s falling productivity ...

A new study published in the journal Nature Medicine suggests that GLP-1 medications such as Ozempic and Wegovy could have a host of other potential benefits beyond treating obesity, including a ...

President Donald Trump’s administration has decided not to cover expensive, high-demand obesity treatments under the federal government's Medicare program. The Centers for Medicare and ...

We recently published a list of 10 Best Pipeline and MLP Stocks to Invest In According to Analysts. In this article, we are going to take a look at where Global Partners LP (NYSE:GLP) stands ...

Pfizer is advancing on a broad front in its attempt to catch up with Novo Nordisk and Eli Lilly in the obesity drug category – but has now decided on a lead candidate. The company said that ...